Pros  | Lower expense ratio. Beats FD returns for both 3Y & 5Y duration.  | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration.  | ||
Cons  | 3Y returns in the bottom 25% of the category.  | 3Y returns in the bottom 25% of the category.  | 
INDMoney rank  | 5/8  | 7/8  | ||
Category,Subcateogry  | Equity,Sector - Healthcare  | Equity,Sector - Healthcare  | ||
Fund Age  | 7 Years  | 12 Years  | ||
Fund Size  | 2762 Cr  | 8114 Cr  | ||
Min Investment  | SIP ₹99 Lumpsum ₹5000  | SIP ₹100 Lumpsum ₹5000  | ||
Expense Ratio  | 0.47%  | 0.91%  | ||
Exit Load  | 1%  | 1%  | ||
Benchmark Index  | BSE Healthcare TR INR  | BSE Healthcare TR INR  | 
No of Holdings  | 33  | 41  | ||
Top 5 Holdings  | Sun Pharmaceuticals Industries Ltd (11.57%) Divi's Laboratories Ltd (7.76%) Glenmark Pharmaceuticals Ltd (6.97%) Apollo Hospitals Enterprise Ltd (6.23%) Cipla Ltd (6.03%)  | Sun Pharmaceuticals Industries Ltd (12.29%) Lupin Ltd (7.26%) Divi's Laboratories Ltd (7.01%) Cipla Ltd (6.48%) Apollo Hospitals Enterprise Ltd (5.92%)  | ||
No of Sectors  | 2  | 1  | ||
Top 3 Sectors  | Health (98.61%) Basic Materials (1.39%)  | Health (100%)  | ||
Equity %  | 99.89%  | 99.47%  | ||
Debt %  | -  | -  | ||
P/E  | 38.6  | 35.64  | ||
P/B  | 5.59  | 5.65  | ||
Credit Quality  | -  | -  | ||
Modified Duration  | -  | -  | ||
YTM  | -  | -  | 
1-Month Return  | 2.95%  | 3.29%  | ||
3-Month Return  | 1.67%  | 0.64%  | ||
6-Month Return  | 8.07%  | 5.6%  | ||
1-Year Return  | 3.05%  | 1.73%  | ||
3-Year Return  | 21.93%  | 21.75%  | ||
5-Year Return  | 19.88%  | 19.39%  | 
Sharpe  | 0.91  | 0.96  | ||
Alpha  | -1.17  | -0.21  | ||
Beta  | 1  | 0.91  | ||
Standard Deviation  | 16.46  | 15.25  | ||
Information Ratio  | -0.53  | -0.48  | 
Description  | Mirae Asset Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run.  | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run.  | ||
Managers  | Vrijesh Kasera  | Sailesh Raj Bhan,Kinjal Desai  |